PC
ABBV icon

PointState Capital’s AbbVie ABBV Stock Holding History

PointState Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,025,000
Closed -$274M – 66
2021
Q4 		$274M Buy
2,025,000
+1,436,000
+244% +$170M 4.54% 2
2021
Q3 		$63.5M Buy
589,000
+439,000
+293% +$50.2M 1.06% 29
2021
Q2 		$16.9M Buy
+150,000
New +$16.9M 0.29% 63

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PointState Capital's ABBV Position: Q3 2022 in Review

PointState Capital sold out of AbbVie (ABBV) in Q3 2022, closing a stake of 39,047 shares — an estimated $5.98M sold.

PointState Capital first reported a position in ABBV in Q2 2013 and held it in 13 quarters. The position peaked at $437M in Q3 2014. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

  • PointState Capital reported no remaining AbbVie position as of Q3 2022 after selling out during the quarter.
  • PointState Capital sold 39,047 AbbVie shares in Q3 2022, an estimated $5.98M.
  • PointState Capital first reported a position in AbbVie in Q2 2013 and held it in 13 quarters.
  • PointState Capital's AbbVie position peaked at $437M in Q3 2014.
  • 2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.